222 related articles for article (PubMed ID: 35198099)
1. The role of IGF-pathway biomarkers in determining risks, screening, and prognosis in lung cancer.
Pohlman AW; Moudgalya H; Jordano L; Lobato GC; Gerard D; Liptay MJ; Seder CW; Borgia JA
Oncotarget; 2022; 13():393-407. PubMed ID: 35198099
[TBL] [Abstract][Full Text] [Related]
2. Value of circulating insulin-like growth factor-associated proteins for the detection of stage I non-small cell lung cancer.
Kubasiak JC; Seder CW; Pithadia R; Basu S; Fhied C; Phillips WW; Daly S; Shersher DD; Yoder MA; Chmielewski G; Edell ES; Maldonado F; Liptay MJ; Borgia JA
J Thorac Cardiovasc Surg; 2015 Mar; 149(3):727-34.e1-3; discussion 734. PubMed ID: 25312225
[TBL] [Abstract][Full Text] [Related]
3. Recent advances of microRNA-based molecular diagnostics to reduce false-positive lung cancer imaging.
Boeri M; Sestini S; Fortunato O; Verri C; Suatoni P; Pastorino U; Sozzi G
Expert Rev Mol Diagn; 2015 Jun; 15(6):801-13. PubMed ID: 25924864
[TBL] [Abstract][Full Text] [Related]
4. Serum and blood based biomarkers for lung cancer screening: a systematic review.
Chu GCW; Lazare K; Sullivan F
BMC Cancer; 2018 Feb; 18(1):181. PubMed ID: 29439651
[TBL] [Abstract][Full Text] [Related]
5. The effect of direct referral for fast CT scan in early lung cancer detection in general practice. A clinical, cluster-randomised trial.
Guldbrandt LM
Dan Med J; 2015 Mar; 62(3):. PubMed ID: 25748876
[TBL] [Abstract][Full Text] [Related]
6. New evidence supporting lung cancer screening with low dose CT & surgical implications.
Dezube AR; Jaklitsch MT
Eur J Surg Oncol; 2020 Jun; 46(6):982-990. PubMed ID: 32113886
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study.
Sozzi G; Boeri M; Rossi M; Verri C; Suatoni P; Bravi F; Roz L; Conte D; Grassi M; Sverzellati N; Marchiano A; Negri E; La Vecchia C; Pastorino U
J Clin Oncol; 2014 Mar; 32(8):768-73. PubMed ID: 24419137
[TBL] [Abstract][Full Text] [Related]
8. [Lung screening].
Milleron B; Gounant V; Khalil A; Couraud S
Rev Pneumol Clin; 2017 Feb; 73(1):27-33. PubMed ID: 27956083
[TBL] [Abstract][Full Text] [Related]
9. Low-dose computed tomography lung cancer screening: Clinical evidence and implementation research.
Lancaster HL; Heuvelmans MA; Oudkerk M
J Intern Med; 2022 Jul; 292(1):68-80. PubMed ID: 35253286
[TBL] [Abstract][Full Text] [Related]
10. Serum insulin-like growth factor (IGF)-I and IGF-binding proteins in lung cancer patients.
Lee DY; Kim SJ; Lee YC
J Korean Med Sci; 1999 Aug; 14(4):401-4. PubMed ID: 10485619
[TBL] [Abstract][Full Text] [Related]
11. Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening.
Sestini S; Boeri M; Marchiano A; Pelosi G; Galeone C; Verri C; Suatoni P; Sverzellati N; La Vecchia C; Sozzi G; Pastorino U
Oncotarget; 2015 Oct; 6(32):32868-77. PubMed ID: 26451608
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of lung cancer screening through low-dose spiral computed tomography among petroleum company staffs in Sichuan-Chongqing Area in 2020].
He ZM; Liu KT; Ren HX; Shen QW
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2022 Mar; 40(3):196-200. PubMed ID: 35439861
[No Abstract] [Full Text] [Related]
13. Performance of lung cancer screening with low-dose CT in Gejiu, Yunnan: A population-based, screening cohort study.
Wei MN; Su Z; Wang JN; Gonzalez Mendez MJ; Yu XY; Liang H; Zhou QH; Fan YG; Qiao YL
Thorac Cancer; 2020 May; 11(5):1224-1232. PubMed ID: 32196998
[TBL] [Abstract][Full Text] [Related]
14. Patient-Level Trajectories and Outcomes After Low-Dose CT Screening in the National Lung Screening Trial.
Iaccarino JM; Silvestri GA; Wiener RS
Chest; 2019 Nov; 156(5):965-971. PubMed ID: 31283920
[TBL] [Abstract][Full Text] [Related]
15. [Value of low-dose spiral computed tomography in lung cancer screening].
Zhang Y; Hong QY; Shi WB; Ou JX; Yang DW; Hu J; Bai CX; Zeng MS; Chen G
Zhonghua Yi Xue Za Zhi; 2013 Oct; 93(38):3011-4. PubMed ID: 24417917
[TBL] [Abstract][Full Text] [Related]
16. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis.
Yu H; Spitz MR; Mistry J; Gu J; Hong WK; Wu X
J Natl Cancer Inst; 1999 Jan; 91(2):151-6. PubMed ID: 9923856
[TBL] [Abstract][Full Text] [Related]
17. Screening values of carcinoembryonic antigen and cytokeratin 19 fragment for lung cancer in combination with low-dose computed tomography in high-risk populations: Initial and 2-year screening outcomes.
Triphuridet N; Vidhyarkorn S; Worakitsitisatorn A; Sricharunrat T; Teerayathanakul N; Auewarakul C; Chungklay N; Krongthong W; Luengingkasoot S; Sornsamdang G; Patumanond J; Sritipsukho P
Lung Cancer; 2018 Aug; 122():243-248. PubMed ID: 30032839
[TBL] [Abstract][Full Text] [Related]
18. Low-dose computed tomography for lung cancer screening: comparison of performance between annual and biennial screen.
Sverzellati N; Silva M; Calareso G; Galeone C; Marchianò A; Sestini S; Sozzi G; Pastorino U
Eur Radiol; 2016 Nov; 26(11):3821-3829. PubMed ID: 26868497
[TBL] [Abstract][Full Text] [Related]
19. Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 molar ratio and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.
Douglas JB; Silverman DT; Pollak MN; Tao Y; Soliman AS; Stolzenberg-Solomon RZ
Cancer Epidemiol Biomarkers Prev; 2010 Sep; 19(9):2298-306. PubMed ID: 20699371
[TBL] [Abstract][Full Text] [Related]
20. Role of insulin-like growth factor-1 signaling pathway in cisplatin-resistant lung cancer cells.
Sun Y; Zheng S; Torossian A; Speirs CK; Schleicher S; Giacalone NJ; Carbone DP; Zhao Z; Lu B
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e563-72. PubMed ID: 22197230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
